BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will highlight its pipeline of DNA vaccines and electroporation delivery technology in a presentation and discuss vaccine product development in panel discussions at the Phacilitate Vaccine Forum Washington 2011, being held January 24-26 at the Grand Hyatt Washington in Washington, D.C.
Dr. Niranjan Y. Sardesai, Inovio’s Senior Vice President, Research & Development, will make a presentation and participate in the panel discussions noted below. Conference link: http://www.phacilitate.co.uk/pages/washington_vac/agenda.html
|
Tuesday, January 25 |
| 11:45 am |
| Focus Session 2 |
| Panel Discussion: Outside in: First-hand experiences of vaccine businesses large and small that have built a foothold in the emerging markets |
| 4:15 pm |
| Focus Session 2 |
| Panel Discussion: What diagnostic applications are gaining greatest interest in the vaccine industry and how are they being developed? |
|
Wednesday, January 26 |
| 12:40 pm |
| Focus Session 2 |
| Presentation: Potent cellular responses to SynCon(TM) DNA vaccines targeting traditional prophylactic vaccine targets |
|
• Role of T-cells in control of transmission versus prevention of infection: Two sides of the same coin? |
| • Discussion of immunogenicity data from VGX-3100 clinical trial for HPV therapy |
| • Evidence from animal models of disease in HIV, influenza, and malaria |
|
1:00 pm |
|
Focus Session 2 |
|
Panel discussion: How might the T-cell approaches be applied to traditional B cell vaccines? |
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio’s proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio’s clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.